Monopar Therapeutics (MNPR) Change in Accured Expenses (2017 - 2025)

Quarterly results put Change in Accured Expenses at $738682.0 for Q4 2025, down 34.92% from a year ago — trailing twelve months through Dec 2025 was $388218.0 (down 23.4% YoY), and the annual figure for FY2025 was $388218.0, down 23.4%.

Monopar Therapeutics has reported Change in Accured Expenses over the past 9 years, most recently at $738682.0 for Q4 2025.

  • Change in Accured Expenses reached $738682.0 in Q4 2025 per MNPR's latest filing, up from $355101.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.2 million in Q4 2022 and bottomed at -$770968.0 in Q1 2025.
  • Median Change in Accured Expenses over the past 5 years was $13156.5 (2022), compared with a mean of $72187.0.
  • The largest annual shift saw Change in Accured Expenses plummeted 10489.49% in 2023 before it skyrocketed 1137.63% in 2025.
  • Over 5 years, Change in Accured Expenses stood at $403967.0 in 2021, then skyrocketed by 196.03% to $1.2 million in 2022, then plummeted by 117.81% to -$212999.0 in 2023, then surged by 632.91% to $1.1 million in 2024, then crashed by 34.92% to $738682.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for MNPR at $738682.0 in Q4 2025, $355101.0 in Q3 2025, and $65403.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 931,000.00
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 70.50 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 107.70 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -176.03 Mn
10 Monopar Therapeutics 466.82 Mn 466.82 Mn - 738,682.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 738,682.00
Dec 31, 2025 738,682.00
Sep 30, 2025 355,101.00
Sep 30, 2025 355,101.00
Jun 30, 2025 65,403.00
Jun 30, 2025 65,403.00
Mar 31, 2025 -770,968.00
Mar 31, 2025 -770,968.00
Dec 31, 2024 1.14 Mn
Dec 31, 2024 1.14 Mn
Sep 30, 2024 28,692.00
Sep 30, 2024 28,692.00
Jun 30, 2024 -345,750.00
Jun 30, 2024 -345,750.00
Mar 31, 2024 -311,239.00
Mar 31, 2024 -311,239.00
Dec 31, 2023 -212,999.00
Dec 31, 2023 -212,999.00
Sep 30, 2023 -496,889.00
Sep 30, 2023 -496,889.00
Jun 30, 2023 -371,724.00
Jun 30, 2023 -371,724.00
Mar 31, 2023 -251,924.00
Mar 31, 2023 -251,924.00
Dec 31, 2022 1.20 Mn
Dec 31, 2022 1.20 Mn
Sep 30, 2022 -277,524.00
Sep 30, 2022 -277,524.00
Jun 30, 2022 562,338.00
Jun 30, 2022 562,338.00
Mar 31, 2022 -2,379.00
Mar 31, 2022 -2,379.00
Dec 31, 2021 403,967.00
Dec 31, 2021 403,967.00
Sep 30, 2021 72,942.00
Sep 30, 2021 72,942.00
Jun 30, 2021 297,452.00
Jun 30, 2021 297,452.00
Mar 31, 2021 -370,394.00
Mar 31, 2021 -370,394.00
Dec 31, 2020 636,970.00
Dec 31, 2020 636,970.00
Sep 30, 2020 -21,418.00
Sep 30, 2020 -21,418.00
Jun 30, 2020 163,152.00
Jun 30, 2020 163,152.00
Mar 31, 2020 -331,106.00
Mar 31, 2020 -331,106.00
Dec 31, 2019 304,229.00
Dec 31, 2019 304,229.00
Sep 30, 2019 -129,416.00
Sep 30, 2019 -129,416.00
Jun 30, 2019 -99,131.00
Jun 30, 2019 -99,131.00
Mar 31, 2019 167,852.00
Mar 31, 2019 167,852.00
Dec 31, 2018 87,658.00
Dec 31, 2018 87,658.00
Sep 30, 2018 -11,248.00
Sep 30, 2018 -11,248.00
Jun 30, 2018 32,544.00
Jun 30, 2018 32,544.00
Mar 31, 2018 -21,270.00
Mar 31, 2018 -21,270.00
Dec 31, 2017 -26,070.00
Dec 31, 2017 -26,070.00
Sep 30, 2017 134,849.00
Sep 30, 2017 134,849.00
Jun 30, 2017 84,719.00
Jun 30, 2017 84,719.00
Mar 31, 2017 53,859.00
Mar 31, 2017 53,859.00